LEGN
NASDAQLegend Biotech Corporation
News · 26 weeks53+33%
2026-03-012026-08-23
Mix3090d
- SEC Filings11(37%)
- Other6(20%)
- Insider5(17%)
- Offering3(10%)
- Analyst3(10%)
- Leadership2(7%)
Latest news
25 items- INSIDERInterim CEO Bash Alan was granted 4,908 units of Ordinary Shares, increasing direct ownership by 16% to 35,142 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- ANALYSTLegend Biotech downgraded by OppenheimerOppenheimer downgraded Legend Biotech from Outperform to Perform
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- PRLegend Biotech Reports Second Quarter 2026 Results and Recent HighlightsCARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 millionExpanded CARVYKTI® availability to 348 global sites and 19 global markets with the launch of IrelandAchieved first clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual‑targeting CAR-T therapy with 100% ORR and 83.3% CR at the higher dose level (DL2) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaStrengthened balance sheet through successful public offering of 7,700,000 American Depository Shares ("ADS") with net proceeds of approximately $212 million, after deducting underwriting discounts and commissions and
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Legend Biotech CorporationSCHEDULE 13G/A - Legend Biotech Corp (0001801198) (Subject)
- INSIDERNew insider Bash Alan claimed ownership of 30,234 units of Ordinary Shares (SEC Form 3)3 - Legend Biotech Corp (0001801198) (Issuer)
- PRLegend Biotech to Host Investor Conference Call on Second Quarter 2026 ResultsBRIDGEWATER N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, August 11, 2026, to review second quarter 2026 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance. Investors and other interested parties may access the live audio webcast via this weblink. A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentations approximately t
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- PRLegend Biotech Announces CEO TransitionYing Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transitionAlan Bash, current President of the CARVYKTI Business Unit, appointed Interim Chief Executive OfficerBoard has initiated a comprehensive search process to identify a permanent successor BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain
- ANALYSTLegend Biotech downgraded by UBS with a new price targetUBS downgraded Legend Biotech from Buy to Neutral and set a new price target of $28.00
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- ANALYSTAnalyst resumed coverage on Legend Biotech with a new price targetAnalyst resumed coverage of Legend Biotech with a rating of Neutral and set a new price target of $35.00
- INSIDERChief Executive Officer Huang Ying gifted 3,382 units of Ordinary Shares, decreasing direct ownership by 1% to 238,490 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- INSIDERDirector Casey Patrick John sold $88,800 worth of Ordinary Shares (6,000 units at $14.80), decreasing direct ownership by 11% to 48,604 units (SEC Form 4)4 - Legend Biotech Corp (0001801198) (Issuer)
- INSIDERChief Executive Officer Huang Ying sold $82,265 worth of Ordinary Shares (5,566 units at $14.78), decreasing direct ownership by 2% to 241,872 units (SEC Form 4) (for tax liability)4 - Legend Biotech Corp (0001801198) (Issuer)
- PRCalidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of DirectorsSAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or "the Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 17, 2026. Dr. Sanders, an experienced veteran of the biopharma industry, will serve as an independent director. "Dr. Sanders has an exceptional track record in developing new technologies," said Calidi Chairman of the Board Jim Schoeneck. "We believe her deep expertise in the clinical development of novel therapeutics will be highly valuable as Calidi advances CLD-401 and its RedTail platform into
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
- SECSEC Form 424B5 filed by Legend Biotech Corporation424B5 - Legend Biotech Corp (0001801198) (Filer)
- PRLegend Biotech Corporation Announces Pricing of Public OfferingBRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares ("ADSs"), each representing two ordinary shares of the Company, at a public offering price of $29.35 per ADS. In addition, Legend Biotech has granted the underwriters a 30-day option to purchase up to an additional 1,155,000 ADSs at the public offering price, less underwriting discounts and commissions. All of the ADSs are being offered by Legend Biotech. The gross proceeds to Legend Biotech from the offering, before deducting
- SECSEC Form 424B5 filed by Legend Biotech Corporation424B5 - Legend Biotech Corp (0001801198) (Filer)
- SECSEC Form F-6EF filed by Legend Biotech CorporationF-6EF - Legend Biotech Corp (0001801198) (Subject)
- PRLegend Biotech Corporation Announces Proposed Public OfferingBRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that it has commenced an underwritten public offering of $225 million of American Depositary Shares ("ADSs"), each representing two ordinary shares of the Company. All of the ADSs will be offered by Legend Biotech. Legend Biotech also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs sold in the public offering at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to
- SECSEC Form 6-K filed by Legend Biotech Corporation6-K - Legend Biotech Corp (0001801198) (Filer)
LEGN FAQ
7 questionsWhat does Legend Biotech Corporation do?
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins...Where does LEGN stock trade?
Legend Biotech Corporation (LEGN) is listed on NASDAQ.What sector and industry is LEGN in?
Legend Biotech Corporation operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Legend Biotech Corporation go public?
Legend Biotech Corporation (LEGN) completed its IPO in 2020.What are analysts saying about LEGN?
Legend Biotech Corporation has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Perform on 2026-08-12. Recent price targets range from $2100.00 to $4000.00.What companies are similar to LEGN?
Notable peers in the same industry include SQZ (SQZ Biotechnologies Company), EDSA (Edesa Biotech Inc.), BBI (Brickell Biotech Inc.). Compare LEGN side-by-side with any of them on Quantisnow.How can I track LEGN on Quantisnow?
Quantisnow aggregates Legend Biotech Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LEGN to receive live email and push alerts on every new disclosure.